Development of CXCL14/BRAK-derived anti-tumour peptide in head and neck squamous cell carcinoma.
| Project/Area Number |
21791816
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Functional basic dentistry
|
|---|
| Research Institution | Kanagawa Dental College |
|---|
Principal Investigator |
MAEHATA Yojiro Kanagawa Dental College, 歯学部, 講師 (80410009)
|
|---|
| Project Period (FY) |
2009 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2009: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 歯科薬理学 / 口腔癌 / CXCL14/BRAK / CXCL8/IL-8 / 血管新生抑制 / Drug Delivery System / 癌 / CXCL14 / BRAK / CXCL8 / IL-8 |
|---|
| Research Abstract |
BRAK, one of a non-ELR motif CXC chemokine, is also known as CXCL14. We previously reported that BRAK has a potent anti-tumor activity in head and neck squamous cell carcinoma cells (HNSCC), but the mechanism of action nor receptor for it is not known. In order to clarify the mechanism of tumor suppression by the BRAK we hypothesized that BRAK inhibits action of angiogenic cytokines such as IL-8 by directly binding to these cytokines. In the first year, we constructed FLAG-BRAK and FLAG-MOCK vectors and transfected these vectors into HSC-2 cells and obtained stably expressing these constructs, and named HSC-2/FRAG-BRAK, and HSC-2/FRAG-MOCK cells. Next year, in order to investigate binding capability of BRAK with these cytokines, we added recombinant proteins IL-8 or VEGF to the culture medium of HSC-2/FRAG-BRAK cells or HSC-2/FRAG-MOCK cells, and collected the culture medium. Following immunopurification of the culture medium, we investigated binding of BRAK with these cytokines and found that BRAK secreted into the culture medium bound with IL-8. Our results raise the possibility to develop angiogenesis inhibitory peptides by use of IL-8-binding peptides derived BRAK.
|
Report
(3 results)
Research Products
(23 results)
-
-
-
[Journal Article] Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma.2009
Author(s)
Ozawa S, Kato Y, Ito S, Komori R, Shiiki N, Tsukinoki K, Ozono S, Maehata Y, Taguchi T, Imagawa-Ishiguro Y, Tsukuda M, Kubota E, Hata R.
-
Journal Title
Cancer Sci. Nov.100(11)
Pages: 2002-2009
NAID
Related Report
-
-
-
-
-
-
-
-
[Presentation] 選択的ROCK阻害剤による抗腫〓性ケモカインBRAK/CXCL14を介した腫〓進展抑制の検討2010
Author(s)
宮本千央, 前畑洋次郎, 小澤重幸, 生駒丈晴, 居作和人, 小林杏, 高橋聡子, 高橋俊介, 吉野文彦, 杉山秀太, 吉田彩佳, 畑隆一郎, 李昌一
Organizer
神奈川歯科大学学会第45回総会
Place of Presentation
横須賀, 神奈川
Year and Date
2010-12-04
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] 頭頚部扁平上皮癌細胞種における酸化ストレスによる腫瘍抑制ケモカインBRAK/CXCL14の発現抑制制御機構の検討2009
Author(s)
宮本千央, 前畑洋次郎, 吉野文彦, 小林杏, 吉田彩佳, 杉山秀太, 高橋聡子, 高橋俊介, 前谷崇志, 川村陽介, 小松知子, 岡田永三, 岡田康江, 辻村傑, 大野晃教, 李昌一
Organizer
第9回日本抗加齢医学会総会
Place of Presentation
港区,東京
Related Report
